Literature DB >> 9620558

A highly conserved processed PTEN pseudogene is located on chromosome band 9p21.

P L Dahia1, M G FitzGerald, X Zhang, D J Marsh, Z Zheng, T Pietsch, A von Deimling, F G Haluska, D A Haber, C Eng.   

Abstract

PTEN/MMAC1/TEP1, encoding a dual-specificity phosphatase, is a tumor suppressor gene which has recently been cloned and mapped to chromosome 10q23.3. We have shown that germline mutations of PTEN are present in individuals with two hamartoma syndromes: Cowden Syndrome, associated with a predisposition to breast and thyroid cancers, and Bannayan-Zonana syndrome. Somatic mutations of PTEN have been reported in a variety of human cancer cell lines, suggesting a potential role for this gene in the pathogenesis of human malignancies. We report the identification of a highly conserved PTEN processed pseudogene, psiPTEN, which shares over 98% homology with the coding region of functional PTEN, and its localisation to chromosome 9p21. The high sequence homology of psiPTEN with the PTEN transcript may potentially lead to misinterpretation when performing mutation analyses based on cDNA templates. Caution should be exerted when using such screening approaches.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620558     DOI: 10.1038/sj.onc.1201762

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  Pten, a protean tumor suppressor.

Authors:  G L Mutter
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis.

Authors:  H Sasaki; M C Zlatescu; R A Betensky; Y Ino; J G Cairncross; D N Louis
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma.

Authors:  Keith M Giles; Brooke E Rosenbaum; Marlies Berger; Allison Izsak; Yang Li; Irineu Illa Bochaca; Eleazar Vega-Saenz de Miera; Jinhua Wang; Farbod Darvishian; Hua Zhong; Iman Osman
Journal:  J Invest Dermatol       Date:  2018-08-24       Impact factor: 8.551

4.  The molecular dynamics of long noncoding RNA control of transcription in PTEN and its pseudogene.

Authors:  Nicholas Lister; Galina Shevchenko; James L Walshe; Jessica Groen; Per Johnsson; Linda Vidarsdóttir; Dan Grander; Sandro F Ataide; Kevin V Morris
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-28       Impact factor: 11.205

5.  A transcribed pseudogene of MYLK promotes cell proliferation.

Authors:  Yoo Jeong Han; Shwu Fan Ma; Gregory Yourek; Yoon-Dong Park; Joe G N Garcia
Journal:  FASEB J       Date:  2011-03-25       Impact factor: 5.191

6.  Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation.

Authors:  X Shan; M J Czar; S C Bunnell; P Liu; Y Liu; P L Schwartzberg; R L Wange
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

7.  Considerations when analyzing the methylation status of PTEN tumor suppressor gene.

Authors:  Michele A Zysman; William B Chapman; Bharati Bapat
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

8.  PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma.

Authors:  James V Lacey; George L Mutter; Brigitte M Ronnett; Olga B Ioffe; Máire A Duggan; Brenda B Rush; Andrew G Glass; Douglas A Richesson; Nilanjan Chatterjee; Bryan Langholz; Mark E Sherman
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

9.  Studying the Oncosuppressive Functions of PTENP1 as a ceRNA.

Authors:  Glena Travis; Nahal Haddadi; Ann M Simpson; Deborah J Marsh; Eileen M McGowan; Najah T Nassif
Journal:  Methods Mol Biol       Date:  2021

10.  Network of Cancer Genes: a web resource to analyze duplicability, orthology and network properties of cancer genes.

Authors:  Adnan S Syed; Matteo D'Antonio; Francesca D Ciccarelli
Journal:  Nucleic Acids Res       Date:  2009-11-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.